BeyondSpring Inc. BYSI
0.58 USD -0.04 (-6.05%)
At closeNov 10, 2026, 4:00 PM EST
0.57 -0.01 -2.54%
After hours · Nov 10, 4:00 PM ET
0.5554 Day range 0.65
0.431 52-week range 2.35
- YTD
- -64.44%
- 1 year
- -69.96%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to…
seekingalpha.com BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript
defenseworld.net BeyondSpring Wins FDA Fast Track for Plinabulin Lung Cancer Program BeyondSpring (NASDAQ: BYSI) said the U.S. Food and Drug Administration has granted Fast Track designation to plinabulin in combination with docetaxel for patients with second- or third-line…
seekingalpha.com BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
globenewswire.com BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
benzinga.com BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
globenewswire.com BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of Neuroblastoma https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1149926
benzinga.com BeyondSpring Appoints Min Qiu As CEO, Effective July 1 Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give…
globenewswire.com BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class…
benzinga.com Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable…
globenewswire.com BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 Meaningful clinical benefit: Median PFS at 7. 0 months, median DoR is 9. 3 months with DCR of 79. 5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable…
globenewswire.com BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
globenewswire.com BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First…
globenewswire.com BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy
defenseworld.net BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why BeyondSpring Inc. (NASDAQ: BYSI - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $1.52 and traded as high as $1.73.…
globenewswire.com BeyondSpring Files 2025 Annual Report on Form 10-K FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
globenewswire.com BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
defenseworld.net Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI) BeyondSpring (NASDAQ: BYSI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two…
defenseworld.net Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) BeyondSpring (NASDAQ: BYSI - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the…
benzinga.com Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
globenewswire.com BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
seekingalpha.com BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) BeyondSpring Inc. (NASDAQ:BYSI ) 2025 Annual Shareholders Meeting Call September 15, 2025 9:00 AM EDT Company Participants Lan Huang - Co-Founder, Chairman & CEO Presentation Unknown Attendee Good…
globenewswire.com BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when…
globenewswire.com BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing…
benzinga.com Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.